Your Messages Inbox
Your Article Summary
See Latest ArticlesCoronado Biosciences and Burnham Institute for Medical Research Sign Exclusive Worldwide License Agreement to Develop and Commercialize Apogossypol for the Treatment of Cancer
Corporate News Releases - The Healthcare Sales & Marketing Network, 05/31/07
Coronado Biosciences Inc., a privately-held, clinical stage biopharmaceutical company focused on the development of novel and proprietary cancer therapeutics, and Burnham Institute for Medical Research (Burnham), a California-based, non-profit medical research institute, announced an agreement granting Coronado exclusive worldwide rights to develop and commercialize Apogossypol. Apogossypol is a small molecule that is believed to inhibit key prosurvival proteins from the Bcl-2 family
Today in M&A/Partnerships...keeping you current
Receive free subspecialty "5-minute updates" via email
Allos Therapeutics Announces an Agreement with Idis for a Named Patient Program for FOLOTYN (pralatrexate injection)
Allos Therapeutics, 12/07/09
Conclusion of a license agreement between BioComber and Chugai on patents related to PURESYSTEM
Chugai Pharmaceutical Co., 12/07/09
Bayer CropScience and FuturaGene sign license agreement for drought tolerance technology in cotton
BayNews International, 12/04/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Amgen Presents Data From First Nplate Study in Children With Chronic ITP
Amgen, 12/08/09
ARIAD Presents Positive Clinical Proof-of-Concept Data on AP24534 in Drug-Resistant Hematological Cancers at ASH Annual Meeting
ARIAD Pharmaceuticals, 12/08/09
Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects
b3c newswire, 12/07/09
Article Search
Sponsor